Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
Multiple myeloma is a malignant hematologic tumor originating from plasma cells, most common in people over 50 years old. The disease progresses insidiously but is highly destructive. If the best treatment window is missed, it can easily cause severe complications such as fractures and renal failure. Current treatment methods are diverse. The key lies in early recognition, timely intervention, and the selection of appropriate strategies based on the patient’s age, constitution, and disease stage to improve survival and quality of life.
Immune reconstruction cell therapy rebuilds the patient’s immune environment, restoring the function of tumor-attacking immune cells such as T cells and NK cells, thereby clearing myeloma cells in the bone marrow and reducing relapse. This treatment has already been applied in clinical interventions for multiple myeloma at United Life International Medical Center with positive outcomes.
① Restores immune recognition: enhances T cell ability to identify M protein and malignant plasma cells;
② Inhibits the bone marrow microenvironment: clears tumor-dependent immunosuppressive factors and blocks its “hotbed”;
③ Reduces relapse rate: follow-up shows a significantly higher sustained negative rate of M protein after treatment.
In practice, tumor patients undergoing surgery, radiotherapy, or chemotherapy often face immune impairment, increased infection risk, and slow recovery. To help patients better tolerate the treatment process and improve quality of life, phased immune reconstruction programs must be scientifically developed for different cycles.
● Short-term plan: Rapidly enhance immunity through immune cell reinfusion to strengthen anti-tumor effects.
● Mid-term plan: Reduce the side effects of conventional treatments, promote recovery, and ensure completion of standardized therapy.
● Long-term plan: Comprehensive enhancement of immunity through immune cell reconstruction, gut immunity restoration, elemental immunity rebuilding, and immune nutritional support, thereby improving quality of life and extending survival.
1. Targeted Drug Therapy
Proteasome inhibitors such as bortezomib and carfilzomib block protein degradation mechanisms in tumor cells, inducing apoptosis. When combined with immunomodulators (such as lenalidomide), efficacy is significantly enhanced, and good responses are achieved even in relapsed myeloma. This type of therapy is usually part of the standard regimen, is well-tolerated, and suitable for most patients.
2. Autologous Hematopoietic Stem Cell Transplantation
Suitable for younger patients in good general condition. After high-dose chemotherapy clears tumor cells, autologous stem cell infusion helps restore bone marrow function and improve long-term remission rates. Transplantation is usually performed with preconditioning chemotherapy and requires specialized institutions, with long-term follow-up still necessary post-transplant.
3. Novel Monoclonal Antibodies and Cell Therapies
In recent years, CD38-targeted monoclonal antibodies (such as daratumumab) and BCMA-targeted CAR-T cell therapy have provided new directions for refractory myeloma. CAR-T therapy precisely identifies and destroys myeloma cells, showing superior responses in relapsed late-stage patients, though it carries certain side effects and should be carefully evaluated.
4. Traditional Chemotherapy Combination Regimens
Regimens such as VCD (bortezomib + cyclophosphamide + dexamethasone) are commonly used for newly diagnosed patients, offering stable courses and wide applicability. They are suitable for patients unable to tolerate intensive therapy. Chemotherapy cycles may be adjusted according to recovery, and some regimens can be combined with targeted drugs to extend remission periods.
5. Minimally Invasive Bone Disease Treatment
In patients with severe osteolytic lesions causing fractures or nerve compression, minimally invasive interventions such as percutaneous vertebroplasty and kyphoplasty can be considered to relieve pain and restore function. These approaches involve small trauma, fast recovery, and are suitable for bone disease lesions at high risk of fracture.
6. Bisphosphonate Therapy
Drugs such as zoledronic acid reduce osteolytic activity, preventing fractures and hypercalcemia. Although they do not directly kill tumor cells, they play an important supportive role in multiple myeloma, relieving bone pain and improving quality of life.
7. Radiotherapy
Used for local pain control or relief of bone lesion compression symptoms. Although myeloma is a systemic disease, some patients experience severe localized pain or concentrated lesions. Radiotherapy helps control local disease and relieve symptoms. It is usually not a standalone treatment but combined with systemic therapy.
8. Supportive Therapy and Rehabilitation Management
This includes infection control, correction of anemia, regulation of calcium-phosphorus metabolism, and psychological support. Patients often suffer from low immunity and reduced quality of life during long-term treatment, making systemic support and rehabilitation management equally important. Regular follow-ups and dynamic disease assessments can significantly extend survival.
Experts at United Life International Medical Center state that multiple myeloma requires comprehensive treatment. Immune reconstruction cell therapy serves as a breakthrough, and combined with transplantation, targeted therapy, and minimally invasive approaches, it can effectively delay disease progression, improve survival, and achieve longer disease-free survival.
